关注
Tim Meyer
Tim Meyer
UCL and Royal Free Hospital
在 ucl.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...
The Lancet 389 (10088), 2492-2502, 2017
40622017
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ...
New England Journal of Medicine 379 (1), 54-63, 2018
21572018
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised …
JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli, JW Valle, ...
The Lancet 389 (10073), 1011-1024, 2017
19312017
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies
L Marelli, R Stigliano, C Triantos, M Senzolo, E Cholongitas, N Davies, ...
Cardiovascular and interventional radiology 30, 6-25, 2007
10622007
Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
RS Finn, M Ikeda, AX Zhu, MW Sung, AD Baron, M Kudo, T Okusaka, ...
Journal of Clinical Oncology 38 (26), 2960-2970, 2020
9742020
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ...
Annals of Oncology 29, iv238-iv255, 2018
9072018
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
JK Ramage, A Ahmed, J Ardill, N Bax, DJ Breen, ME Caplin, P Corrie, ...
gut 61 (1), 6-32, 2012
6892012
A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability
M Rodriguez-Peralvarez, TV Luong, L Andreana, T Meyer, AP Dhillon, ...
Annals of surgical oncology 20, 325-339, 2013
6352013
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
JM Llovet, T De Baere, L Kulik, PK Haber, TF Greten, T Meyer, R Lencioni
Nature reviews Gastroenterology & hepatology 18 (5), 293-313, 2021
5692021
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind …
T Meyer, R Fox, YT Ma, PJ Ross, MW James, R Sturgess, C Stubbs, ...
The lancet Gastroenterology & hepatology 2 (8), 565-575, 2017
4662017
Role of tumour markers in monitoring epithelial ovarian cancer
T Meyer, GJS Rustin
British journal of cancer 82 (9), 1535-1538, 2000
4442000
Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis
G Germani, M Pleguezuelo, K Gurusamy, T Meyer, G Isgrò, AK Burroughs
Journal of hepatology 52 (3), 380-388, 2010
4032010
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
L Kadalayil, R Benini, L Pallan, J O'beirne, L Marelli, D Yu, A Hackshaw, ...
Annals of oncology 24 (10), 2565-2570, 2013
3652013
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II …
JW Valle, H Wasan, P Johnson, E Jones, L Dixon, R Swindell, S Baka, ...
British journal of cancer 101 (4), 621-627, 2009
3622009
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
R Gillmore, S Stuart, A Kirkwood, A Hameeduddin, N Woodward, ...
Journal of hepatology 55 (6), 1309-1316, 2011
3572011
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ...
Journal of Clinical Oncology 37 (31), 2825-2834, 2019
3542019
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
JM Francis, A Kiezun, AH Ramos, S Serra, CS Pedamallu, ZR Qian, ...
Nature genetics 45 (12), 1483-1486, 2013
3492013
Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
JM Llovet, A Villanueva, JA Marrero, M Schwartz, T Meyer, PR Galle, ...
Hepatology 73, 158-191, 2021
3182021
Consensus on biomarkers for neuroendocrine tumour disease.
GJ Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC ...
Lancet Oncololgy 16 (9), e435-46., 2015
317*2015
Mechanisms of tumour metastasis
T Meyer, IR Hart
European journal of cancer 34 (2), 214-221, 1998
3131998
系统目前无法执行此操作,请稍后再试。
文章 1–20